SG/CALL/ECKERT & ZIEGLER STRAHLEN/45/0.1/21.06.24 Share Price

Warrant

DE000SV6R1F4

End-of-day quote Deutsche Boerse AG
- EUR - Intraday chart for SG/CALL/ECKERT & ZIEGLER STRAHLEN/45/0.1/21.06.24
Current month-57.65%
1 month-76.00%
Date Price Change
21/06/24 - -
20/06/24 0.072 +157.14%
19/06/24 0.028 -15.15%
18/06/24 0.033 -46.77%
17/06/24 0.062 -10.14%

Deutsche Boerse AG

Last update June 21, 2024 at 01:02 pm

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying ECKERT & ZIEGLER SE
IssuerLogo Issuer Société Générale Société Générale
WKN SV6R1F
ISINDE000SV6R1F4
Date issued 25/05/2023
Strike 45
Maturity Today (-0 Days)
Parity 10 : 1
Emission price 1.1
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Spread 0.007
Spread %8.86%

Company Profile

Eckert & Ziegler SE is a Germany-based Company, which is a provider of isotope technology for medical, scientific and industrial use with focus on cancer therapy, industrial radiometry and nuclear-medical imaging. The Company operates through three segments: Radiation Therapy, Isotope Products and Radiopharma. The Radiation Therapy segment operates through Eckert & Ziegler BEBIG and produces and distributes medical products for the treatment of cancer using brachytherapy. The Isotope Products segment provides sealed and unsealed radiation sources for medical imaging, industrial gauging, measurement and analysis, reference, calibration and environmental monitoring sources and solutions, as well as bulk radioisotopes for pharmaceutical, therapeutic and industrial product manufacturers. The Radiopharma segment specializes in molecular imaging and nuclear medicine, and supplies various radiopharmaceuticals, radiochemicals and related equipment.
Sector
-
More about the company

Ratings for Eckert & Ziegler SE

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Consensus: Eckert & Ziegler SE

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
45.5 EUR
Average target price
62.5 EUR
Spread / Average Target
+37.36%
Consensus